Approve of the use through DOM (2005) Approved for use through DOM (2005) Approved for use through DOM (2005) (DOM (2005) Approved for use through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for the set through DOM (2005) (DOM (2005) Approved for through DOM (2005)

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional)	
FY 2008 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		007180-69 US	
Application Number 10/521,570		Filed January 18,	2005
For Novel Inhibitors of Ubiquitin Isopeptidases			
Art Unit 1614		Examiner Anna Pagonakis	
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filling a reply in the above identified application.			
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):			
	Fee	Small Entity Fee	
One month (37 CFR 1.17(a)(1))	\$120	\$60	\$
x Two months (37 CFR 1.17(a)(2))	\$460	\$230	\$230
Three months (37 CFR 1.17(a)(3))	\$1050	\$525	\$
Four months (37 CFR 1.17(a)(4))	\$1640	\$820	s
Five months (37 CFR 1.17(a)(5))	\$2230	\$1115	\$
x Applicant claims small entity status. See 37 CFR 1.27.			
A check in the amount of the fee is enclosed.			
Rayment by credit card.			
The Director has already been authorized to charge fees in this application to a Deposit Account.			
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 502679 I have enclosed a duplicate copy of this sheet.			
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
I am the applicant/inventor.			
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).			
attorney or agent of record. Registration Number			
attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34			
Registration number in aduling unities of CFR 1.34			
Signature Sugnature			
Jennifer M. McCallum, Ph.D., Esq.		303-828-0655	
Typed or printed name		Telephone Number	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.			
Total of forms are submitted.			

The collection of information is required by 3 CFR 1-136(a). The information is required to obtain or retain a benefit by the public which is to the lond by the USPYO in processor an application. Controlled by the symmetry of 3 U.S. C. 12 and 2 CFR 1-11 and 14. The collection is estimated to sket of immates to complete, including pathering, preparing, and submitting the completed application form to the USPYO. Time will vary depending upon the individual case. Any comments on the amount of time by our quite to complete this form and/or suggestions for retailurg this bustom, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1490, Alexandriu, VA 2231-31450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEMD TO: Commissioner for Pathents, P.O. Box 1450, Max andriu, VA 2231-31450.